BioSpace News Archive

Special Meetings to Be Held on October 29, 2020 Unanimously Recommend Stockholders Vote “For” the Merger and Other Proposals Set Forth in the Definitive Proxy Statement Transaction on Track to Close by End of Fourth Quarter of 2020

NANO-X IMAGING LTD, an innovative medical imaging technology company, issued a statement in response to unusual trading activities that occurred on September 15, 2020.

Cigna Corporation announces the launch of Evernorth, a new brand for its growing, high-performing health services portfolio.

Company Also Expands Advisory and Leadership Teams with New Member of Scientific Advisory Board, Chairman of DiNAQOR UK, and General Counsel

Acceleron Pharma Inc., a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, announced the appointment of Laura J. Hamill to its Board of Directors.

Confirmed overall response rate (ORR) of 21% in the dose-escalation stage across all doses, confirmed ORR 33% at the highest and selected Phase 2 dose Target tumor shrinkage was observed in 37% of patients Preliminary data show activity in patients with melanoma, Merkel cell carcinoma (MCC), and cutaneous squamous cell carcinoma (CSCC) Phase 2 arms in both MCC and CSCC are currently recruiting CHICAGO & CAMBRIDGE,

Accelerating clinical research is a top priority across sites, sponsors, and CROs. To help speed research, more sites are using Veeva SiteVault Free for managing study documentation an

Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, and LabCorp (NYSE: LH), a leading global life sciences company, today announced a collaboration with LabCorp’s drug development business, Covance. LabCorp will participate in Tempus’s TIME Trial® Network and the companies will work together to accelerate patient enrollment

Pascal Biosciences Inc. (TSXV:PAS) oday Dr. Patrick Gray, CEO of Pascal Biosciences, will present advancements in each of Pascal’s three cannabinoid programs. The title of his presentation is “Identifying and Validating Mechanism of Action In Vivo and In Vitro”.

Production companies can qualify for 30 percent in tax credits using BioIQ’s COVID-19 testing solution to safely bring workers back and resume filming in Georgia. [16-September-2020] ATLANTA , Sept. 16, 2020 /PRNewswire/ -- BioIQ , an aggregator of testing solutions and optimizer of lab capacity for leading employers and health plans, announces that it is the first